Matches in SemOpenAlex for { <https://semopenalex.org/work/W3024392979> ?p ?o ?g. }
- W3024392979 endingPage "1768" @default.
- W3024392979 startingPage "1753" @default.
- W3024392979 abstract "The development of immune checkpoint inhibitors (ICI) represents a major milestone in immune‐oncology. Over the years these agents have demonstrated efficacy in an increasing array of malignancies. Despite this success however, significant challenges remain. Novel approaches to both drug development and trial design are required to incorporate the unique pharmacokinetic and pharmacodynamic properties of ICIs. Further, it has also been established that the benefit of ICIs is limited to only a subset of patients. The molecular interactions between native immune cells and tumorigenesis and progression represent an active area of biomarker research, and elucidating the mechanisms of response and resistance is crucial to develop rational trial designs for the next wave of immune‐oncology (IO) clinical trials, particularly in patients with primary and/or acquired resistance. Efforts are now being made to integrate both biological and clinical information using novel multi‐omic approaches which are now being developed to further elucidate the molecular signatures associated with IO treatment response and resistance and enable rational drug development and trial design processes. As such, precision IO and the ability to deliver patient‐specific choices for ICI monotherapies or combination therapies has become an increasingly tangible goal. We herein describe the current landscape in ICI drug development and discuss the challenges and future directions in this exciting and evolving era in immune‐oncology." @default.
- W3024392979 created "2020-05-21" @default.
- W3024392979 creator A5010459048 @default.
- W3024392979 creator A5039790911 @default.
- W3024392979 creator A5082371740 @default.
- W3024392979 creator A5088186975 @default.
- W3024392979 date "2020-06-13" @default.
- W3024392979 modified "2023-10-17" @default.
- W3024392979 title "Novel strategies in immune checkpoint inhibitor drug development: How far are we from the paradigm shift?" @default.
- W3024392979 cites W1572739876 @default.
- W3024392979 cites W1622259963 @default.
- W3024392979 cites W1809627231 @default.
- W3024392979 cites W1846272699 @default.
- W3024392979 cites W1869127618 @default.
- W3024392979 cites W1916602633 @default.
- W3024392979 cites W1940241680 @default.
- W3024392979 cites W1947060780 @default.
- W3024392979 cites W1965215390 @default.
- W3024392979 cites W1970875728 @default.
- W3024392979 cites W1971685703 @default.
- W3024392979 cites W1973251492 @default.
- W3024392979 cites W1974059338 @default.
- W3024392979 cites W1982488143 @default.
- W3024392979 cites W1990411699 @default.
- W3024392979 cites W1990675339 @default.
- W3024392979 cites W1991581123 @default.
- W3024392979 cites W1997656349 @default.
- W3024392979 cites W2004619271 @default.
- W3024392979 cites W2005475183 @default.
- W3024392979 cites W2005891936 @default.
- W3024392979 cites W2012853695 @default.
- W3024392979 cites W2023980114 @default.
- W3024392979 cites W2024447346 @default.
- W3024392979 cites W2025421597 @default.
- W3024392979 cites W2038448543 @default.
- W3024392979 cites W2040060890 @default.
- W3024392979 cites W2044588680 @default.
- W3024392979 cites W2045478673 @default.
- W3024392979 cites W2048397943 @default.
- W3024392979 cites W2049553585 @default.
- W3024392979 cites W2058033125 @default.
- W3024392979 cites W2059050919 @default.
- W3024392979 cites W2066671159 @default.
- W3024392979 cites W2069640685 @default.
- W3024392979 cites W2074546881 @default.
- W3024392979 cites W2080886891 @default.
- W3024392979 cites W2082796931 @default.
- W3024392979 cites W2084515830 @default.
- W3024392979 cites W2097227099 @default.
- W3024392979 cites W2097288420 @default.
- W3024392979 cites W2109274792 @default.
- W3024392979 cites W2112225610 @default.
- W3024392979 cites W21125662 @default.
- W3024392979 cites W2114017759 @default.
- W3024392979 cites W2118982164 @default.
- W3024392979 cites W2127733313 @default.
- W3024392979 cites W2134644618 @default.
- W3024392979 cites W2141989396 @default.
- W3024392979 cites W2144995154 @default.
- W3024392979 cites W2152897456 @default.
- W3024392979 cites W2160103588 @default.
- W3024392979 cites W2160834915 @default.
- W3024392979 cites W2165925577 @default.
- W3024392979 cites W2166084034 @default.
- W3024392979 cites W2166662937 @default.
- W3024392979 cites W2173235643 @default.
- W3024392979 cites W2173701885 @default.
- W3024392979 cites W2177405394 @default.
- W3024392979 cites W2185075416 @default.
- W3024392979 cites W2198093519 @default.
- W3024392979 cites W2207200267 @default.
- W3024392979 cites W2275606382 @default.
- W3024392979 cites W2284926981 @default.
- W3024392979 cites W2301695049 @default.
- W3024392979 cites W2318605753 @default.
- W3024392979 cites W2338494814 @default.
- W3024392979 cites W2345952503 @default.
- W3024392979 cites W2392329487 @default.
- W3024392979 cites W2394605535 @default.
- W3024392979 cites W2395714980 @default.
- W3024392979 cites W2427476638 @default.
- W3024392979 cites W2463775439 @default.
- W3024392979 cites W2482216880 @default.
- W3024392979 cites W2484958770 @default.
- W3024392979 cites W2501488762 @default.
- W3024392979 cites W2503851771 @default.
- W3024392979 cites W2512255557 @default.
- W3024392979 cites W2521282167 @default.
- W3024392979 cites W2527905628 @default.
- W3024392979 cites W2528124008 @default.
- W3024392979 cites W2529928819 @default.
- W3024392979 cites W2531874455 @default.
- W3024392979 cites W2549481046 @default.
- W3024392979 cites W2549531711 @default.
- W3024392979 cites W2552342083 @default.
- W3024392979 cites W2554081523 @default.
- W3024392979 cites W2554947920 @default.
- W3024392979 cites W2561263099 @default.